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We have previously described several potent dual inhibitors of Plasmodium falciparum (Pf ) growth
characterized by the presence of statine, a β-hydroxyl amino acid able to inhibit parasite's plasmepsins
(PLMs). While investigating the mechanism of action of these inhibitors, new compounds derived from statine
were synthesized, which lost the ability to inhibit PLMs, but retained a significant Pf growth inhibition.
Further structural simplifications showed that the inhibition of Pf viability was ascribed to a new
pharmacophore never described before as antimalarial.Introduction
Malaria has a massive impact on human health, being one of
the major infections in the world causing 219 million clinical
cases and about 660000 deaths in 2010, mainly children
under the age of five.1 The most deadly parasite among the
five Plasmodium species that causes human malaria is Plasmo-
dium falciparum (Pf ).
Artemisinin-combination therapies (ACTs) represent the
major forms of intervention against malaria; however, the
spread of drug resistance, as recently reported for artemisinin
derivatives2,3 may become a major public health problem,
hindering malaria treatment. Spreading of resistance to first
line drugs over the past few decades has led to intensification
of the monitoring of their efficacy, to ensure proper manage-
ment of clinical cases and early detection of changing pat-
terns of resistance in order to revise national malaria treat-
ment policies. This issue, combined with few commercially
available drugs and an increased focus on limiting malaria
transmission, is the basis for the urgent need of new antima-
larials with innovative mechanism of action to fight against
the onset of cross-resistance and expand physician tools for
malaria control and eventually elimination.
Plasmepsins (PLMs) are aspartic proteases that, in cooper-
ation with other proteases, participate in the haemoglobin
digestion in the parasitic food vacuole.4 This process is cru-
cial for the development of the parasite and its blockageleads to the Plasmodium death. Although the haemoglobin
digestion process appears to be a good pharmacological tar-
get, molecules with a useful in vivo efficacy have not been
obtained yet. During our studies interesting results were gen-
erated by applying the “double-drug” approach:5–9 we synthe-
sized molecules characterized by the presence of statine, a
β-hydroxyl amino acid able to inhibit aspartic proteases, such
as PLMs, joined with the 8-aminoquinolinic ring system (1)
derived from primaquine (PQ) or a hepatic schizonticidal
atovaquone (2) or the 4-aminoquinolinic ring system (3)
derived from chloroquine (CQ) (Fig. 1).
These compounds were potent PLMs inhibitors and
showed an antimalarial activity at concentrations significantlyun., 2015, 6, 1173–1177 | 1173
s.
MedChemCommConcise Article
Pu
bl
ish
ed
 o
n 
06
 M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i M
ila
no
 o
n 
19
/0
6/
20
15
 1
2:
53
:1
8.
 
View Article Onlinelower than any PLMs inhibitor previously reported. The anti-
malarial activity was also accompanied by low cytotoxicity
and high selectivity towards human proteases.6 The com-
pounds shown in Fig. 1 are the most active representative for
each class.
During our studies, discrepancies in the relationships
between the inhibition of PLM2 and of Pf growth become evi-
dent. By comparing compounds 1, 2 and 4 that present
quinolinic substituents (Table 1), 2 and 4 showed very similar
values of PLM2 inhibition. However compound 2, having the
quinolinic ring system derived from CQ, presented an anti-
malarial activity significantly higher (4–7 times) than com-
pound 4 against the CQ-resistant, W2 strain. Furthermore,
compound 4 was the best PLM2 inhibitor and the worst
antimalarial.
To test the contribution of PLM2 inhibition to the antima-
larial activity of the double drugs, we designed compounds
5–7 using compounds 1, 2 and 4 as models, replacing statine,
responsible for PLM2 inhibition, with leucine. (Table 1)1174 | Med. Chem. Commun., 2015, 6, 1173–1177
Table 1 Enzyme inhibition and antiplasmodial activity of compounds 1–2 and
Entry R R′
1b
2c
4c
5
6
7
CQ
a Results are the mean of two experiments performed in duplicate. b Fro
tested.Results and discussion
Compounds 5–7 were prepared using the dipeptidic benzyl
ester derivative of oxybisbenzoic acid 11 (Scheme 1) that
was synthesized by coupling Boc-Leu with butylamine
leading to amide 8, which after acidic cleavage of Boc
reacted with Boc-Ile generating dipeptide 9. After depro-
tection, dipeptide 9 underwent a coupling reaction with
4-Ĳ4-Ĳ(benzyloxy)carbonyl)phenoxy)benzoic acid 10 leading to
compound 11 (Scheme 1).
Compound 5 was obtained by coupling the dipeptide
derivative of primaquine 13 with oxybisbenzoic ester 11, after
simultaneous deprotection by hydrogenolysis. (Scheme 2).
Compounds 6 and 7 were prepared according to Scheme 3.
A nucleophilic substitution of chlorine in position 4 of 4,7-
dichloroquinoline with a large excess of 1,3-diaminopropane
followed by coupling with Boc-Ala led to intermediate 14. The
Boc-deprotected intermediate 14 underwent a further coupling
reaction with Cbz-Leu to generate dipeptide 15 (Scheme 3).This journal is © The Royal Society of Chemistry 2015
4–7
PLM2 Ki (nM) D10 IC50 (nM)
a W2 IC50 (nM)
a
26.3 200 300
3.8 114 64
2.6 161 474
n.a. 37 104
n.a. 43 39
n.a. 63 54
n.t. 23 412
m ref. 6. c From ref. 9. n.a.: no inhibition observed at 1 μM. n.t.: not
Scheme 2 Reagents and conditions: (a) BocAlaOH, HBTU, HOBt,
NMM; (b) HCl 4 N, dioxane; (c) CbzLeuOH, HBTU, HOBt, NMM; (d) Pd/
C, H2, MeOH; (e) HBTU, HOBt, NMM.
Scheme 3 Reagents and conditions: (a) propane-1,3-diamine, 140 °C;
(b) BocAlaOH, HBTU, HOBt, NMM; (c) HCl 4 N, dioxane; (d) Pd/C, H2,
MeOH (e) CbzLeuOH, HBTU, HOBt, NMM;. (f) HBTU, HOBt, NMM.
Table 2 Inhibition of β-haematin formation12
Entry R BHIAa
5 >8
6 0.79
CQ 1.36
PQ >10
a The IC50 represents the molar equivalents of test compounds
relative to haematin required to inhibit β-haematin formation by 50%.
Scheme 1 Reagents and conditions: (a) n-butylamine, N,N,N′,N′-
tetramethyl-O-Ĳ1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU),
1-hydroxybenzotriazoleĲHOBt), 4-methylmorpholine (NMM); (b) HCl 4
N, dioxane; (c) BocIleOH, HBTU, HOBt, NMM; (d) HBTU, HOBt, NMM.
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View Article OnlineCompound 7 was obtained by a coupling reaction after
simultaneous one-pot deprotection of benzyl ester 11 andThis journal is © The Royal Society of Chemistry 2015dipeptide 15. As expected, during catalytic hydrogenation, the
chlorine atom in position 7 was removed10 (Scheme 3).
Compound 6 was obtained by a coupling reaction between
deprotected intermediates 14 and 11 (Scheme 3).
Compounds 5–7 were tested against W2, CQ-resistant and
D10, CQ-sensitive Pf strains,11 as well as for PLM2 inhibition
and the results are shown in Table 1. As expected compounds
5–7 were unable to inhibit PLM2 proteolytic activity, but they
showed an antimalarial activity significantly higher than their
statine analogues against both Pf strains.
Interestingly, while compound 4 and 5 showed cross-
resistance with CQ, compounds 6 and 7 demonstrated a simi-
lar activity on both D10 and W2 strains. Compound 6 being
the most active was also tested for cytotoxicity against normal
human fibroblast (FDH)6 and against a macrophage cell line
(HMEC-1), showing an effect only in the micromolar range
(FDH, IC50: 17.99 ± 8.7 μM; HMEC-1, IC50: 17.58 ± 7.8 μM)
with a good therapeutic index (approx. 450).
Therefore, compounds 5–7 are potent inhibitors of Pf
growth, but they do not act through PLMs inhibition. To
verify if these compounds share the same mechanism of
action as CQ, we assessed the ability of compounds 5 and 6
to inhibit β-haematin formation using the BHIA method pre-
viously described.12
Table 2 shows that compound 6, characterised by the
4-aminoquinoline ring system, inhibits β-haematin formation
better than CQ (IC50 0.79 vs. 1.36 of CQ), whereas compound
5 is inactive as PQ.
This is consistent with the previous data showing that the
8-aminoquinolinic ring system is not able to interfere with
β-haematin formation.12
The lack of inhibition of β-haematin formation and the
loss of PLM2 inhibition paired with the good antiplasmodial
activity of compound 5, led us to suppose that this new class
of Pf inhibitors may owe its activity to a different mechanism
of action.Med. Chem. Commun., 2015, 6, 1173–1177 | 1175
Table 4 LLEa values for compounds 5–7, 16, 18, and 19
Entry LLE (pH 7.4) D10 LLE (pH 7.4) W2
5 0.52 0.07
6 1.59 1.63
7 1.80 1.87
16 2.74 3.12
18 3.35 3.41
19 2.99 3.04
a LLE13 = pIC50 − c logD (pH 7.4).14
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View Article OnlineTo verify this hypothesis, compounds 16–18 were synthe-
sized replacing the quinolinic substructure with a short alkyl
chain. The basic tertiary amine was introduced in compound
16 to improve aqueous solubility which is otherwise
extremely low. Compound 17 shows the same substituent on
both sides and compound 18 presents a one amino acid
shortened peptide chain. The influence of the dipeptide
IleLeu on the other side of the oxybisbenzoic scaffold was
evaluated by removing Ile (19) and the entire substituent
(20), thus achieving further reduction of the peptide charac-
ter and molecular weight.
Compounds 16–18 were synthesized similarly to com-
pound 5 (Scheme 2) using in the first step the appropriate
amine (see the ESI†) while for the preparation of compounds
19 and 20, a slightly different synthetic route was adopted
(see the ESI†). Compounds 16–20 were tested against W2,
CQ-resistant and D10, CQ-sensitive Pf strains and the results
are shown in Table 3.
Compounds 16, 18 and 19 showed an antiplasmodial
activity in the nanomolar range while compound 17 resulted
considerably less active compared to compound 7, probably
due to its limited aqueous solubility. Compound 20 showed
very limited antiplasmodial activity. Compounds 18 and
19 were also tested for cytotoxicity against normal human
fibroblast (FDH)6 ((18) IC50: 16.3 ± 4.9 μM; (19) IC50: 23.0 ±
7.3 μM) showing an effect similar to compound 6. Compound
18 showed a good therapeutic index (>100).1176 | Med. Chem. Commun., 2015, 6, 1173–1177
Table 3 Antiplasmodial activity of compounds 7, 16–20
Cmp R D10 IC50
(nM)a
W2 IC50
(nM)a
7 63 54
16 345 143
17 1981 1620
18 121 103
19 357 314
20 n.a. n.a.
a Results are the mean of two experiments performed in duplicate.
n.a. IC50 > 5 μg ml
−l.To assess the attractiveness of compounds 5–7, 16, 18,
and 19 as new hits, the values of ligand lipophilicity effi-
ciency (LLE) were calculated.13 Table 4 shows that the substi-
tution of the quinolinic ring system with a tertiary amine
resulted in a clear improvement of LLE. Compounds 18 and
19 are particularly attractive because they show very similar
IC50 values against CQ-sensitive and CQ-resistant Pf strains
and the highest LLE value.
Conclusions
On the basis of these results and the fact that 18 and 19 do
not present any known antimalarial pharmacophoric group,
it is likely that these molecules owe their activity to a new
mechanism of action.
Considering that, any new antimalarial drug needs to be
effective against drug-resistant strains, but also affordable for
those in need in developing countries, it is essential to
develop molecules with an inexpensive synthesis. The removal
of the non-natural β-hydroxyl amino acid statine greatly facili-
tated the synthesis reducing, the inherent costs. Therefore, we
believe that compounds 18 and 19 are good starting points
for developing a new class of antimalarial agents.
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